Upstream Bio (UPB) Cash & Equivalents (2023 - 2026)

Upstream Bio's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $96.7 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 35.63% year-over-year to $96.7 million; the TTM figure through Mar 2026 stood at $96.7 million (up 35.63% YoY), while the FY2025 annual figure was $101.6 million, down 68.83% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $96.7 million, down from $101.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $325.9 million in Q4 2024, with the low at $25.8 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $47.3 million (2024), against an average of $81.6 million.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents surged 1161.53% in 2024, then slumped 68.83% in 2025.
• Upstream Bio's Cash & Equivalents stood at $25.8 million in 2023, then soared by 1161.53% to $325.9 million in 2024, then plunged by 68.83% to $101.6 million in 2025, then fell by 4.78% to $96.7 million in 2026.
• Business Quant data shows UPB's Cash & Equivalents at $96.7 million in Q1 2026, $101.6 million in Q4 2025, and $72.2 million in Q3 2025.